Lilly
commune in Eure, France
Positive
Negative
Entity sentiment
Reports
News
Opinions
Statements
Articles
Relations
business Feb 23, 2026, 6:31 AM
Novo Nordisk stock crashes after disappointing obesity trial results - Novo Nordisk stock dropped to a 52-week low after disappointing trial results.
- The REDEFINE 4 phase 3 trial failed to demonstrate non-inferiority of CagriSema in weight loss compared to tirzepatide.
- Management remains optimistic about future trials and the drug's potential despite the setback.
100
2026 All rights reserved
2026 All rights reserved